Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data-Reference-Cited by-同舟云学术

Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data

Published:2018-01 Issue:1 Volume:13 Page:46-53
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Thakur Manish K.,Ruterbusch Julie J.,Schwartz Ann G.,Gadgeel Shirish M.,Beebe-Dimmer Jennifer L.,Wozniak Antoinette J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Second lung cancers in patients after treatment for an initial lung cancer;Johnson;J Natl Cancer Inst,1998

3. Survival in patients with metachronous second primary lung cancer;Ha;Ann Am Thorac Soc,2015

4. Reduced lung-cancer mortality with low-dose computed tomographic screening;Aberle;N Engl J Med,2011

5. National Comprehensive Cancer Network. NCCN guidelines in oncology: lung cancer screening. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Accessed March 20, 2017.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Overlooked Cornerstone in Precise Medicine: Personalized Postoperative Surveillance Plan for NSCLC;JTO Clinical and Research Reports;2024-08

2. Second Primary Lung Cancer – An Emerging Issue in Lung Cancer Survivors;Journal of Thoracic Oncology;2024-07

3. Real-World Survival Comparisons Between Radiotherapy and Surgery for Metachronous Second Primary Lung Cancer and Predictions of Lung Cancer–Specific Outcomes Using Machine Learning: Population-Based Study;JMIR Cancer;2024-06-12

4. Histology-specific standardized incidence ratio improves the estimation of second primary lung cancer risk;BMC Medicine;2024-05-03

5. Pulmonary mucinous adenocarcinoma: An overview of pathophysiology and advancements in treatment;Heliyon;2024-05